### Briefing: Off-Label GLP-1 Prescriptions for Addiction Surge in Telehealth For popular diabetes and obesity medications known as GLP-1s, addiction medicine is one of the promising next acts. Baseline Therapeutics is studying a GLP-1 receptor agonist in alcohol, cocaine, and methamphetamine use disorders; Altimmune is testing one called pemvidutide for alcohol use disorder. Addiction medicine specialists are hopeful that the Food and Drug Administration may soon approve a new medication for alcohol use disorder…
Key points
### Briefing: Off-Label GLP-1 Prescriptions for Addiction Surge in Telehealth
For popula…: ### Briefing: Off-Label GLP-1 Prescriptions for Addiction Surge in Telehealth
For popular diabetes and obesity medications known as GLP-1s, addiction medicine is one of the promising next acts.
Baseline Therapeutics is studying a GLP-1 receptor agonist in alcohol, cocaine, and metha…: Baseline Therapeutics is studying a GLP-1 receptor agonist in alcohol, cocaine, and methamphetamine use disorders; Altimmune is testing one called pemvidutide for alcohol use disorder.
Addiction medicine specialists are hopeful that the Food and Drug Administration may soon…: Addiction medicine specialists are hopeful that the Food and Drug Administration may soon approve a new medication for alcohol use disorder, the first in two decades.
Sources checked by our analysis pipeline: 1
For the popular diabetes and obesity medications known as GLP-1s, addiction medicine is one of many possible promising next acts.
Eli Lilly is investigating a new drug, brenipatide, and testing it in alcohol use disorder. A new company called Baseline Therapeutics is studying a GLP-1 receptor agonist in alcohol, cocaine, and methamphetamine use disorders; Altimmune is testing one called pemvidutide for alcohol. Addiction medicine specialists are hopeful that the Food and Drug Administration may soon approve a new medication for alcohol use disorder — the first in two decades.
But some telehealth platforms that specialize in treating addiction aren’t waiting. In the last year, a few companies have begun to market off-label prescriptions of GLP-1s, both branded and compounded, to treat alcohol use disorder and other addictions.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
The journey from the family's first encounter with symptoms to the recognition of the inherited condition "it" took decades, with each generation contributing to the knowledge base. The process involved hundreds of researchers dedicating their careers to understanding the rare disease, leading to the creation of a name that finally provided clarity. The recognition of the disease's existence meant that families could start to manage the symptoms and seek the appropriate care, rather than just coping with the unkno…
A Bengaluru district consumer commission has ordered a beauty clinic to pay Rs 1.11 lakh in damages and litigation costs to a woman who suffered facial burns following a laser hair removal procedure. The commission, which held the clinic liable for deficiency in service and unfair trade practice, directed the clinic to refund Rs 1,100 with interest, pay Rs 1 lakh in damages for skin damage and mental agony, and Rs 10,000 towards litigation costs. The clinic was also directed to comply with the order within 45 days…
France reports its first human case of the Shamonda virus, a rare and potentially deadly strain, as confirmed by the World Health Organization. The patient, a 35-year-old man from the southwestern region, was hospitalized after experiencing severe symptoms including fever, coughing, and shortness of breath. The virus, identified as a variant of the previously known "Shamonda" virus, has been circulating in the region for several months. The patient has been isolated and monitored closely by medical authorities to…